Affordable Access

deepdyve-link
Publisher Website

Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.

Authors
  • Chen, Yun1
  • Wang, Chunyu1
  • Xu, Fanxi1
  • Ming, Fengyu1
  • Zhang, Hainan2
  • 1 Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China. , (China)
  • 2 Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Clinical therapeutics
Publication Date
Oct 01, 2019
Volume
41
Issue
10
Pages
2112–2136
Identifiers
DOI: 10.1016/j.clinthera.2019.07.009
PMID: 31445679
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

IV immunoglobulin (Ig) therapy has been widely used for the treatment of neurologic disorders, autoimmune diseases, immunodeficiency-related diseases, blood system diseases, and cancers. In this review, we summarize the efficacy and tolerability of IVIg and SCIg therapy in neurologic diseases. We summarized and analyzed the efficacy and tolerability of IVIg and SCIg in neurologic diseases, by analyzing the literature pertaining to the use of IVIg and SCIg to treat nervous system diseases. In clinical neurology practice, IVIg has been shown to be useful for the treatment of new-onset or recurrent immune diseases and for long-term maintenance treatment of chronic diseases. Moreover, IVIg may have applications in the management of intractable autoimmune epilepsy, paraneoplastic syndrome, autoimmune encephalitis, and neuromyelitis optica. SCIg is emerging as an alternative to IVIg treatment. Although SCIg has a composition similar to that of IVIg, the applications of this therapy are different. Notably, the bioavailability of SCIg is lower than that of IVIg, but the homeostasis level is more stable. Current studies have shown that these 2 therapies have pharmacodynamic equivalence. In this review, we explored the efficacy of IVIg in the treatment of various neurologic disorders. IVIg administration still faces many challenges. Thus, it will be necessary to standardize the use of IVIg in the clinical setting. SCIg administration is a novel and feasible treatment option for neurologic and immune-related diseases, such as chronic inflammatory demyelinating polyradiculoneuropathy and idiopathic inflammatory myopathies. As our understanding of the mechanisms of action of IVIg improve, potential next-generation biologics can being developed. Copyright © 2019. Published by Elsevier Inc.

Report this publication

Statistics

Seen <100 times